John Newman
Stock Analyst at Canaccord Genuity
(2.16)
# 2,921
Out of 5,182 analysts
96
Total ratings
44.05%
Success rate
-5.29%
Average return
Main Sectors:
Stocks Rated by John Newman
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| LCTX Lineage Cell Therapeutics | Initiates: Buy | $9 | $1.57 | +473.25% | 1 | Apr 28, 2026 | |
| TYRA Tyra Biosciences | Initiates: Buy | $50 | $35.80 | +39.66% | 1 | Apr 6, 2026 | |
| TNGX Tango Therapeutics | Initiates: Buy | $30 | $24.50 | +22.47% | 1 | Apr 2, 2026 | |
| MCRB Seres Therapeutics | Maintains: Buy | $22 | $7.14 | +208.13% | 11 | Mar 13, 2026 | |
| CADL Candel Therapeutics | Maintains: Buy | $25 | $6.15 | +306.50% | 3 | Mar 13, 2026 | |
| ALLO Allogene Therapeutics | Maintains: Buy | $14 | $2.21 | +533.48% | 4 | Mar 13, 2026 | |
| BNTX BioNTech SE | Maintains: Buy | $171 | $100.98 | +69.34% | 9 | Mar 11, 2026 | |
| ATRA Atara Biotherapeutics | Downgrades: Hold | $25 → $6 | $4.83 | +24.22% | 7 | Jan 13, 2026 | |
| ACET Adicet Bio | Maintains: Buy | $128 → $18 | $7.62 | +136.22% | 7 | Jan 6, 2026 | |
| ACLX Arcellx | Maintains: Buy | $130 | - | - | 10 | Dec 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $850 → $1,057 | $737.25 | +43.37% | 20 | Dec 4, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $10 | $1.87 | +436.19% | 1 | Dec 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $126 | $101.91 | +23.64% | 1 | Nov 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $21 | $10.68 | +96.63% | 2 | Oct 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $8 | $1.42 | +462.83% | 1 | Mar 5, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $38 → $43 | $6.95 | +518.71% | 1 | Jul 3, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $5 | $0.92 | +444.78% | 2 | Jun 23, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $52 → $44 | $24.70 | +78.14% | 9 | Feb 16, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $30 → $38 | $13.47 | +182.10% | 2 | Oct 17, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $12 → $27 | $1.58 | +1,608.86% | 2 | Sep 13, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Speculative Buy | n/a | $16.12 | - | 1 | Sep 13, 2017 |
Lineage Cell Therapeutics
Apr 28, 2026
Initiates: Buy
Price Target: $9
Current: $1.57
Upside: +473.25%
Tyra Biosciences
Apr 6, 2026
Initiates: Buy
Price Target: $50
Current: $35.80
Upside: +39.66%
Tango Therapeutics
Apr 2, 2026
Initiates: Buy
Price Target: $30
Current: $24.50
Upside: +22.47%
Seres Therapeutics
Mar 13, 2026
Maintains: Buy
Price Target: $22
Current: $7.14
Upside: +208.13%
Candel Therapeutics
Mar 13, 2026
Maintains: Buy
Price Target: $25
Current: $6.15
Upside: +306.50%
Allogene Therapeutics
Mar 13, 2026
Maintains: Buy
Price Target: $14
Current: $2.21
Upside: +533.48%
BioNTech SE
Mar 11, 2026
Maintains: Buy
Price Target: $171
Current: $100.98
Upside: +69.34%
Atara Biotherapeutics
Jan 13, 2026
Downgrades: Hold
Price Target: $25 → $6
Current: $4.83
Upside: +24.22%
Adicet Bio
Jan 6, 2026
Maintains: Buy
Price Target: $128 → $18
Current: $7.62
Upside: +136.22%
Arcellx
Dec 8, 2025
Maintains: Buy
Price Target: $130
Current: -
Upside: -
Dec 4, 2025
Maintains: Buy
Price Target: $850 → $1,057
Current: $737.25
Upside: +43.37%
Dec 3, 2025
Initiates: Buy
Price Target: $10
Current: $1.87
Upside: +436.19%
Nov 12, 2025
Initiates: Buy
Price Target: $126
Current: $101.91
Upside: +23.64%
Oct 21, 2025
Maintains: Buy
Price Target: $21
Current: $10.68
Upside: +96.63%
Mar 5, 2025
Initiates: Buy
Price Target: $8
Current: $1.42
Upside: +462.83%
Jul 3, 2024
Maintains: Buy
Price Target: $38 → $43
Current: $6.95
Upside: +518.71%
Jun 23, 2023
Reiterates: Buy
Price Target: $5
Current: $0.92
Upside: +444.78%
Feb 16, 2022
Maintains: Buy
Price Target: $52 → $44
Current: $24.70
Upside: +78.14%
Oct 17, 2017
Maintains: Buy
Price Target: $30 → $38
Current: $13.47
Upside: +182.10%
Sep 13, 2017
Maintains: Buy
Price Target: $12 → $27
Current: $1.58
Upside: +1,608.86%
Sep 13, 2017
Downgrades: Speculative Buy
Price Target: n/a
Current: $16.12
Upside: -